» Articles » PMID: 27605433

Secreted Primary Human Malignant Mesothelioma Exosome Signature Reflects Oncogenic Cargo

Overview
Journal Sci Rep
Specialty Science
Date 2016 Sep 9
PMID 27605433
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant mesothelioma (MM) is a highly-aggressive heterogeneous malignancy, typically diagnosed at advanced stage. An important area of mesothelioma biology and progression is understanding intercellular communication and the contribution of the secretome. Exosomes are secreted extracellular vesicles shown to shuttle cellular cargo and direct intercellular communication in the tumour microenvironment, facilitate immunoregulation and metastasis. In this study, quantitative proteomics was used to investigate MM-derived exosomes from distinct human models and identify select cargo protein networks associated with angiogenesis, metastasis, and immunoregulation. Utilising bioinformatics pathway/network analyses, and correlation with previous studies on tumour exosomes, we defined a select mesothelioma exosomal signature (mEXOS, 570 proteins) enriched in tumour antigens and various cancer-specific signalling (HPGD/ENO1/OSMR) and secreted modulators (FN1/ITLN1/MAMDC2/PDGFD/GBP1). Notably, such circulating cargo offers unique insights into mesothelioma progression and tumour microenvironment reprogramming. Functionally, we demonstrate that oncogenic exosomes facilitate the migratory capacity of fibroblast/endothelial cells, supporting the systematic model of MM progression associated with vascular remodelling and angiogenesis. We provide biophysical and proteomic characterisation of exosomes, define a unique oncogenic signature (mEXOS), and demonstrate the regulatory capacity of exosomes in cell migration/tube formation assays. These findings contribute to understanding tumour-stromal crosstalk in the context of MM, and potential new diagnostic and therapeutic extracellular targets.

Citing Articles

Exosome: an overview on enhanced biogenesis by small molecules.

Bavafa A, Izadpanahi M, Hosseini E, Hajinejad M, Abedi M, Forouzanfar F Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39862264 DOI: 10.1007/s00210-024-03762-9.


Intercellular transfer of multidrug resistance mediated by extracellular vesicles.

Yang A, Sun H, Wang X Cancer Drug Resist. 2024; 7:36.

PMID: 39403600 PMC: 11472569. DOI: 10.20517/cdr.2024.84.


Serum Calretinin and Genetic Variability as a Prognostic and Predictive Factor in Malignant Mesothelioma.

Zupanc C, Franko A, Strbac D, Kovac V, Dolzan V, Goricar K Int J Mol Sci. 2024; 25(1).

PMID: 38203360 PMC: 10778798. DOI: 10.3390/ijms25010190.


Small and Large Extracellular Vesicles Derived from Pleural Mesothelioma Cell Lines Offer Biomarker Potential.

Ahmadzada T, Vijayan A, Vafaee F, Azimi A, Reid G, Clarke S Cancers (Basel). 2023; 15(8).

PMID: 37190292 PMC: 10136721. DOI: 10.3390/cancers15082364.


Exosome Mediated Cancer Therapeutic Approach:Present Status and Future Prospectives.

Roy A, As S, Ganesh P, Saravanan M, Sunny B Asian Pac J Cancer Prev. 2023; 24(2):363-373.

PMID: 36853283 PMC: 10162618. DOI: 10.31557/APJCP.2023.24.2.363.


References
1.
Berger W, Setinek U, Hollaus P, Zidek T, Steiner E, Elbling L . Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. J Cancer Res Clin Oncol. 2005; 131(6):355-63. DOI: 10.1007/s00432-004-0653-9. View

2.
Pietras K, Ostman A . Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res. 2010; 316(8):1324-31. DOI: 10.1016/j.yexcr.2010.02.045. View

3.
Kunicka T, Soucek P . Importance of ABCC1 for cancer therapy and prognosis. Drug Metab Rev. 2014; 46(3):325-42. DOI: 10.3109/03602532.2014.901348. View

4.
El Andaloussi S, Mager I, Breakefield X, Wood M . Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12(5):347-57. DOI: 10.1038/nrd3978. View

5.
Caffarel M, Coleman N . Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma. J Pathol. 2014; 232(4):386-90. PMC: 4260121. DOI: 10.1002/path.4305. View